Maijie Life Sciences Completes Tens of Millions of RMB Series A Financing to Build a Multi-Product Regenerative Repair Materials Platform

VCBeat learned that recently, Shenzhen Medgen Life Sciences Co., Ltd. ("Medgen Life Sciences") has completed its first round of financing worth tens of millions of yuan.Exclusively invested by Huaxi Yuanyou Fund.This round of financing will be used for Medgen Life Sciences' continuous innovation, clinical research, and promotion in the regenerative repair materials product line, further solidifying the company's technological leadership in multi-disciplinary regenerative repair platforms such as medical aesthetics, orthopedics, and sports medicine.Changhai Capital served as the exclusive financial advisor for this round of financing.

China's bone repair materials market size is expected to reach 9.69 billion yuan in 2023, with a five-year CAGR of 19.8%, far exceeding the overall growth level of the global industry; orthopedics sees an annual net increase of 4.7 million cases of demand gap, and the demand for other categories such as medical aesthetics and dentistry is also increasing year by year. High-biomimetic, cost-effective repair materials produced in China are expected to rapidly gain volume in the short term.

The current mainstream direction of artificial bone repair materials is bionic composite materials similar to natural human bones. Bionic composite materials feature highly biomimetic composition and structure, excellent biocompatibility, and osteoconductivity. During the process of guiding new bone regeneration, these materials are gradually replaced by newly formed bone tissue through creeping substitution and eventually become fully integrated. The degradation rate of the material matches the rate of new bone regeneration.Medgen Life Sciences' Self-Developed New Generation of Inducible Bone Repair Material SeriesIt is the first injectable artificial bone in China. Compared with the current PLA/PLGA/hydroxyapatite artificial bones on the market, it is more convenient to operate and performs better in biological characteristics such as bone conduction. It is used for filling bone defect gaps and fissures in limbs and spine under low-load conditions; during the preliminary exploratory large-animal spinal fusion experiment phase, it demonstrated good osteoinductive effects, comparable to autologous bone. The product is currently in the registration stage.

Rotator cuff tears are one of the common tendon injuries in orthopedics/sports medicine.Current Clinical Focus and ChallengesCurrently, no rotator cuff patch products have been approved for marketing in China.Still a blank space. The core self-developed composite rotator cuff patch by Medgen Life Sciences addresses the issues of insufficient mechanical strength and susceptibility to immune rejection found in existing market products, featuringGood Repair Effect。This project undertakes the major technical challenges of Shenzhen City.

In China's light medical aesthetics filler materials, the existing market for medical aesthetic injectables is worth tens of billions, with high technical barriers. New regenerative injectable products can achieve sales of billions within 2-3 years after launch. In the field of regenerative injectables, hydroxyapatite with superior performance has been widely used abroad, while in China, its application remains a blank.Hydroxyapatite-based regenerative injectables in China remain a blue ocean.As a niche new force, collagen is expected to see continuous growth in penetration through different market focuses. Moreover, due to the lack of technological breakthroughs in the spatial structure of recombinant collagen,The market share of animal-derived collagen will continue to expand.

Under the trend of "pursuing natural beauty," regenerative materials achieve facial rejuvenation effects by promoting the regeneration of the body's own fibroblasts and collagen. Compared to traditional fillers with shorter durations, regenerative materials offer natural, progressive, and long-lasting filling effects, making medical aesthetics more appealing.From the simple filling era to the regeneration era.

Driven by the supply and demand of medical aesthetics products and compliance policies, the scale of the medical aesthetics market continues to grow. Additionally, the different properties, softness and hardness, and microstructures of various materials determine the applications of different products.Multi-material, Multi-technology Layout, Enriching Product Reserves - Medgen Life SciencesBetter meet the needs of the rapid iteration of medical aesthetics products and the increasingly refined market.

Medgen Life Sciences is a supplier specializing in the research and development of natural porous hydroxyapatite repair materials and long-chain triple-helix collagen materials for multiple fields such as orthopedics, sports medicine, dentistry, and medical aesthetics. It is a comprehensive Class III medical device company. The company owns over 10,000 square meters of production facilities and R&D centers in Shenzhen, has collaborated on more than ten projects with universities and research institutes, and holds over 40 independent intellectual property rights. It is recognized as a technology-based small and medium-sized enterprise and a high-tech enterprise by the state.

Medgen Life Sciences Focuses on Novel Regenerative Materials, Offering Self-Developed Next-Generation Repair and Filler Materials with Higher Biocompatibility to Address Clinical Pain Points Across Multiple Scenarios. The company specializes in animal extraction, possessing a full set of foundational technologies, with an emphasis on sourcing and processing natural raw materials. It has established itself as a platform company centered on medical aesthetics, spanning across medical aesthetics, orthopedics, sports medicine, and dentistry. On the raw material front, the company independently controls its upstream supply chain to ensure stable, consistent, compliant, and effective raw material supply. In terms of processing, the company masters a complete set of preliminary treatment techniques, ensuring the safety of clinical trials and product supply in compliance with national regulations. Medgen Life Sciences boasts two major technological platforms: hydroxyapatite regeneration product transformation and biomedical collagen cross-linking technology, providing comprehensive regenerative biomaterial solutions across the entire industry chain.

The team has extensive and diverse experience, originating from a top-tier academician-led team combined with abundant clinical resources in China. They have been deeply engaged in biomedical materials for decades. The founding team has over ten years of experience working in well-known companies both domestically and internationally, possessing rich expertise in the research and development of Class III and Class II medical device products, clinical studies, quality production, and operations. They also have sales and management experience in medical aesthetics, orthopedics, and sports medicine sectors. The team initially invested in building their own raw material and process platform.

Medgen Life Sciences is methodically expanding its layout in research and development, marketing, and sales. Next, the research and clinical trials for medical aesthetics and sports medicine products will gradually commence; orthopedic products will obtain certification and be launched on the market soon. In the future, the company will maintain a balanced and rapid development in both serious medicine and consumer healthcare sectors.

For this round of financing,Medgen Life Sciences Founder and CEO Deng SilingExpressed: We are very grateful to Huaxi Yuan You Fund for its recognition of the company and the strong assistance from Changhai Capital in this round of financing! Regenerative repair materials have huge market potential globally. Over the years, Medgen Life Sciences has been deeply engaged in the research, development, and transformation of tissue regenerative repair products. Through real and effective clinical feedback, it has successfully developed regenerative repair products that improve patients' health in orthopedics and aesthetic medicine fields while meeting the needs of beauty seekers. In the future, with the support of investors, the company will continue to uphold its product advantages, refine its product technology, and further promote the development of the regenerative repair field.

Liang Shuang, Partner of Huaxi Yuan You FundHydroxyapatite has been used as a medical raw material in the healthcare field for many years. Natural porous hydroxyapatite offers unique advantages in tissue repair, filling, and induced regeneration. In recent years, China's medical aesthetics consumer base has developed a relatively mature market awareness of regenerative formulations based on hydroxyapatite. Medgen Life Sciences' R&D pipeline, which focuses on natural ingredients including porous hydroxyapatite and collagen as its technological core, is highly anticipated by the compliant consumer market and will undoubtedly gain widespread recognition in the field of regenerative medicine.

Wang Keshu, Partner of VCBeatExpressed: We are very pleased to have the opportunity to cooperate with Medgen Life Sciences, assisting them in completing their first round of financing and establishing a leading position in the field of regenerative repair materials. Medgen Life Sciences insists on using natural raw materials, and its various regenerative repair products not only fill the gap in the domestic market but also lead in effectiveness, safety, and cost-performance while being fully compliant. We look forward to Medgen Life Sciences continuously bringing valuable products to China's regenerative repair field in the future!

Hainan Huaxi Yuanyou Fund is a 1 billion RMB industrial investment fund jointly established by Huaxi Bio, Lancy Hanin, Hainan Free Trade Port Fund, and Haikou National High-Tech Industrial Development Zone Fund. This is the first equity investment fund initiated by Huaxi Bio for the industrial incubation of startups in the medical health consumer products sector.

Changhai Capital is a financial advisor focused on the healthcare sector, providing companies with in-depth and customized financing strategies and services. The team has extensive industry experience in the fields of life sciences, medical devices, diagnostics, and healthcare services. It has led and participated in the financing of several high-profile companies, assisting them in rapid growth and maximizing their value.